amorphous calcium carbonate (AMOR 18) / Amorphical Ltd - LARVOL DELTA

Amorphous Calcium Carbonate (ACC) in moderate-to-severe Crohn’s disease: 24-Week and long-term results from a randomized, placebo-controlled trial with open-label extension (ECCO-IBD 2026) - "The dual mechanism of ACC, localized acid neutralization and calcium delivery, represents a novel therapeutic approach in CD. Additional data from the long-term follow-up and controlled studies will further establish the efficacy of ACC in CD."

Clinical • Crohn's disease • Immunology • Inflammatory Bowel Disease

Amorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer Patients (PRNewswire) - "Data is expected in Q3 of 2026."

P2 data • Trial status • Pancreatic Cancer

Amorphous calcium carbonate as a novel potential treatment for osteoarthritis in dogs: a pilot clinical study. (PubMed, Front Vet Sci) - "The relatively small number of dogs limited the statistical power of the pilot study in evaluating the efficacy and safety of ACC. Study results support the conduct of larger, appropriately powered studies using similar assessments to confirm whether ACC may be a safe and effective treatment for OA in dogs."

Clinical • Journal • Immunology • Inflammation • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology

Amorphous calcium carbonate enhances osteogenic differentiation and myotube formation of human bone marrow derived mesenchymal stem cells and primary skeletal muscle cells under microgravity conditions. (PubMed, Life Sci Space Res (Amst)) - "Similarly, hBM-MSCs were differentiated significantly better into osteocytes in the presence of ACC leading to increased calcium deposits. The results, combined with previous data, support the use of ACC as an advantageous supplement for preventing muscle and bone deterioration in outer space conditions, facilitating extended extraterrestrial voyages and colonization."

Journal • Muscular Atrophy

Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients. (clinicaltrials.gov) - P1/2 | N=66 | Completed | Sponsor: Amorphical Ltd. | Recruiting ➔ Completed | N=100 ➔ 66 | Trial completion date: Dec 2021 ➔ Jun 2023 | Trial primary completion date: Dec 2021 ➔ Jun 2023

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects (clinicaltrials.gov) - P1 | N=11 | Terminated | Sponsor: Amorphical Ltd. | N=20 ➔ 11 | Unknown status ➔ Terminated; Slow recruitment

Enrollment change • Trial termination • Oncology • Solid Tumor

Improving Function,Welfare of Late-stage Cancer Subjects by ACC (clinicaltrials.gov) - P1 | N=10 | Terminated | Sponsor: Amorphical Ltd. | N=20 ➔ 10 | Unknown status ➔ Terminated; Slow recreuitment

Enrollment change • Trial termination • Gastrointestinal Cancer • Lung Cancer • Oncology • Solid Tumor

Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Amorphical Ltd. | N=60 ➔ 0 | Trial completion date: Apr 2017 ➔ Dec 2023 | Unknown status ➔ Withdrawn | Trial primary completion date: Apr 2017 ➔ Dec 2023

Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

AMCS009: A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism (clinicaltrials.gov) - P=N/A | N=10 | Terminated | Sponsor: Amorphical Ltd.

New trial • Endocrine Disorders • Hypoparathyroidism • Renal Disease

Amorphous Calcium Carbonate Shows Anti-Cancer Properties That are Attributed to Its Buffering Capacity. (PubMed, Cancers (Basel)) - "This study supports the ACC anti-malignant buffering hypothesis by demonstrating decelerated tumor growth, reduced cathepsin B activity, and altered gene expressions to produce anti-cancerous effects."

Journal • Lung Cancer • Metabolic Disorders • Oncology • Solid Tumor • CTSB

The effect of amorphous calcium carbonate as a culture media supplement on embryonic development of murine sibling embryos. (PubMed, J Assist Reprod Genet) - "In conclusion, the ACC demonstrates a rapid modulation effect for restoring media optimal pH. ACC can inhibit cathepsin B activity during in vitro culture of fibroblast cells. The beneficial impact of ACC on cleavage mouse embryos is likely due to an improved buffering effect causing slower pH media variations, which may enhance quality and implantation potential of embryos following in vitro culture."

Journal • Preclinical • CTSB